How to Design an ABM-Aligned Ideal Customer Profile (ICP)
Every December, the business development team at a mid-size contract research organization would gather at a hotel for their annual planning meeting. Over three days, each BD rep would stand up and present their account priorities for the coming year — which companies they were going after, which they were treating as top-tier targets, and why. The problem: every rep had developed their own criteria. Some prioritized large pharma because of deal size. Others focused on mid-size biotechs because they were easier to get meetings with. Some tiered accounts based on geography. Others based it on relationships. The result was a fragmented, inconsistent commercial strategy that made it nearly impossible for marketing to support in any coordinated way.
When a structured ABM program was proposed, the first task wasn't setting up a platform or designing ads. It was building a shared, data-backed targeting framework — a real ICP — derived from analysis of which accounts had historically generated the most revenue, what their shared characteristics were, and how to translate those characteristics into consistent, actionable targeting criteria for the whole team.
That work transformed the annual planning process. It also provided the foundation that made everything else in the ABM program possible.
Why the ICP Is the Foundation of Everything in ABM
Account-based marketing lives or dies on targeting precision. Every subsequent decision in an ABM program — which accounts to include, what messaging to develop, which personas to reach, how to structure campaigns — flows from a clear, specific, commercially-grounded ICP.
Most B2B organizations have something they call an ICP. The problem, as the ABM Guide makes clear, is that those ICPs are often undocumented, outdated, or built more on assumptions and intuition than on actual business data. In life sciences especially, where market conditions shift with funding cycles, therapeutic pipeline evolution, and regulatory changes, an ICP that was accurate two years ago may no longer reflect the real profile of your best customers today.
The most important step in building a strong ICP is the one most often skipped: go back to your own revenue data and let it tell you who your best customers actually are.
Start With the 80/20 Analysis
In most B2B organizations, revenue distribution follows a consistent pattern: roughly 80% of revenue comes from approximately 20% of accounts. That top 20% — the accounts with the largest contracts, the best retention, the strongest expansion history — is the empirical starting point for your ICP.
Pull the data. Look at your highest-revenue accounts over the past two to three years. Look at average deal value by account, time to close, renewal rates, and expansion revenue. Identify the top tier — these are your Tier 1 accounts — and then look carefully at what they have in common.
Those commonalities are your ICP. Not what you think your best customers look like, not what your BD team has assumed over the years, but what your actual revenue data tells you is true.
From there, build out additional tiers. Tier 2 accounts are strong-fit companies that represent meaningful revenue potential but don't quite match the profile of your very best customers. Tier 3 accounts are worth reaching with broad, scalable marketing but don't warrant the level of investment required for more targeted ABM approaches. This tiered structure becomes the architecture of your entire ABM program: One-to-One treatment for Tier 1, One-to-Few for Tier 2, One-to-Many or broad demand gen for Tier 3.
What an ABM-Aligned ICP Looks Like for Pharma and Biotech Companies
Generic B2B ICP frameworks typically focus on firmographic criteria — company size, industry vertical, revenue range, geography. In life sciences, these firmographics are a starting point, but the most meaningful targeting criteria are considerably more specific.
The following factors are commonly relevant when building ICP criteria for pharma and biotech targets:
Pipeline stage and asset maturity. For many life science service and technology providers, the most relevant signal is where a target company's assets sit in development. A company with three programs in early discovery is a very different prospect than one with a Phase 2 asset that just received FDA Fast Track designation. Depending on your offering, you may find that accounts with assets at a specific stage — late preclinical, Phase 1/2, or pre-NDA — are consistently your best customers. Documenting that stage specificity in your ICP sharpens targeting significantly.
Therapeutic area and modality. Not all pipelines are created equal from a targeting perspective. If your solution has particular depth in oncology biomarker work, a company developing cardiovascular small molecules may be a technically eligible but strategically poor fit. ICP segments based on therapeutic area (oncology, rare disease, neurology, immunology, etc.) and modality (small molecule, biologics, cell therapy, gene therapy, antibody-drug conjugates) allow you to match your specific expertise and capability to the accounts most likely to value it.
Company size and organizational maturity. Headcount and revenue are useful proxies, but for biotech specifically, pipeline size and funding stage are often more meaningful. A 200-person biotech with a single Phase 3 asset and a recent Series D is a different proposition than a 200-person biotech running four early-phase programs on a Series B runway. Commercial maturity matters too: a company with a dedicated clinical operations team and an established outsourcing function will have a faster path to vendor selection than one building those capabilities for the first time.
Funding status and financial signals. Recent funding events are one of the clearest intent signals in life science ABM. A Series C or D round, a successful IPO, or a significant partnership or licensing deal typically signals that capital has been allocated to advance programs — and that investment in supporting services and technologies is likely to follow. Companies without recent funding events, or with visible financial stress (layoffs, program cancellations, strategic reviews), are lower-priority targets regardless of how well they fit other ICP criteria.
Outsourcing orientation. Some companies build in-house capability wherever possible; others run lean and outsource heavily. If you are a CRO, a central lab, or a technology vendor, knowing whether a target company has a history of outsourcing work similar to yours is an important qualifying criterion. This can often be inferred from job postings, LinkedIn profiles of the commercial team, or known relationships with peer organizations.
Geography and regulatory context. Clinical trial activity, site networks, and regulatory strategy can all vary significantly by geography. If your solution has particular depth in EU regulatory pathways, or your service infrastructure is concentrated in North America, this should be reflected in your ICP rather than targeting globally and filtering retroactively.
Segmenting When Your Value Proposition Varies
The ABM Guide makes an important distinction that is frequently overlooked in ICP construction: if your organization offers multiple products or services with meaningfully different value propositions, a single monolithic ICP won't serve you well. You need segmented ICPs — one for each major audience group — with distinct messaging frameworks for each.
A contract service organization offering both early-phase bioanalytical services and late-phase central lab services, for example, is effectively selling to two different audiences with different stages of need, different buying committee compositions, and different primary concerns. Treating those as one audience produces messaging that is generic to both and compelling to neither.
Each segmented ICP should document: the firmographic and life sciences-specific profile of the segment, the typical buying committee composition, the primary business challenges driving a need for your solution, and the core value propositions most relevant to that audience. This segmentation becomes the blueprint for everything downstream — persona targeting, content development, ad messaging, and landing page design.
Account Tiering: Not All ICP Accounts Are Equal
Once you have a working ICP — and any relevant segments — the next step is to recognize that even among accounts that all meet your criteria, there is a wide range in terms of potential deal value, strategic importance, and sales readiness. Treating every qualifying account with the same level of marketing investment is a recipe for poor ROI. This is where account tiering comes in.
Tiering divides your ICP account list into groups that warrant different levels of commercial resource — and directly determines which ABM approach (One-to-One, One-to-Few, or One-to-Many) is applied to each group.
A common and effective framework uses three tiers:
Tier 1 — Strategic. These are your highest-value targets: accounts with the potential for exceptionally large, multi-year engagements that would represent a material impact on annual revenue. They represent a perfect match with your strongest service or product capabilities, at exactly the right stage of development. This group is typically small — often no more than 5 to 10 accounts, and rarely more than 5% of your total ICP list. Because the revenue potential justifies it, these accounts receive a fully bespoke One-to-One ABM treatment: customized landing pages, account-specific content, and executive-level BD engagement.
Tier 2 — Scale. The next 20 to 30% of your ICP list falls here. These accounts have strong clinical and scientific fit, a high likelihood of closing, and represent healthy deal values with good operational alignment. They may not individually justify the resource intensity of Tier 1, but they are by no means generic targets. The appropriate approach is One-to-Few ABM: grouping accounts by a shared characteristic — the same therapeutic area, the same development phase, the same outsourcing model — and deploying messaging and content tailored to the needs of that cluster.
Tier 3 — Programmatic. The remaining accounts that meet your baseline ICP criteria sit in Tier 3. They may not yet demonstrate the revenue potential or buying signals to warrant deeper investment, but they are worth keeping in view. One-to-Many ABM — broad programmatic advertising, content syndication, educational webinars — is the right approach here. The goal is dual: build brand awareness within this pool, and monitor for signals (a new funding round, a regulatory filing, a pipeline advancement) that suggest an account is ready to be elevated to Tier 2.
It is worth noting that tiering is not a static assignment. Accounts should move between tiers as market conditions change and new information becomes available. A Tier 3 biotech that closes a Series C and announces a new Phase 2 program is no longer a Tier 3 account. Your commercial team needs a defined process — typically tied to the life-science-specific intent signals discussed in later posts in this series — for identifying when an account should be elevated and what happens next when it is.
The practical value of tiering extends beyond resource allocation. It also creates internal clarity and accountability. Marketing knows which accounts to invest in most deeply. The SDR team knows which qualified accounts are highest priority for outreach. BD knows which opportunities to prioritize for executive engagement. When tiers are agreed upon and documented, the commercial team stops debating priorities and starts executing against them.
Add Persona Targeting to Complete the Picture
An ICP defines which companies to target. Persona targeting defines which people within those companies to reach. Both are required for ABM.
With your ICP segments in place, the next step is to document the buying committee for each segment — the typical roles involved in a purchase decision, and the titles that align to each role. Sales and BD input is essential here: they know who is actually in the room when a deal is being decided, whose concerns can stall a deal, and who tends to be the internal champion.
The output is a matrix of ICP segments and persona types, each with associated title keywords for targeting. This becomes the foundation for all persona-level ad targeting, content development, and outreach sequencing in your ABM campaigns.
Treat the ICP as a Living Document
A well-designed ICP is not a one-time exercise. Markets shift, pipelines move, your own offerings evolve, and the profile of your best-fit customer changes accordingly. Building in an annual ICP review — with input from marketing, sales, BD, and ideally a commercial leadership sponsor — ensures that your ABM program continues to target the right accounts as your business grows.
The companies that get the most from ABM are not always those with the most sophisticated technology or the largest campaign budgets. They are the ones with the clearest, most commercially aligned picture of who they are trying to win — and the discipline to keep that picture current.
More articles
Beyond the Account: How ABM Uncovers Buying Committees and Why That’s Key
The shift from lead-based marketing to account-based marketing was a meaningful evolution. Instead of chasing individual contacts and hoping the right person would eventually surface, ABM focused commercial resources on a defined set of high-value organizations, and measured success at the account level rather than the lead level.
But account-level thinking alone is not the complete picture. An account is not a buyer. A buying committee is.
The most sophisticated B2B marketing programs have taken a further step: targeting not just accounts, but the specific groups of individuals within those accounts who are collectively responsible for a purchase decision. Understanding who those people are, what each of them needs to see before they will advocate for your solution, and how to reach all of them simultaneously is what separates ABM programs that generate real pipeline from those that generate account-level engagement without commercial traction.
This post explains the buying committee reality in B2B life sciences, how ABM can be used to surface and engage every relevant stakeholder, and how the pattern of engagement across a buying group becomes one of the most valuable signals in the entire commercial program.
Why Targeting Accounts Is Necessary but Not Sufficient
When a B2B life science company runs an ABM campaign targeting a specific biotech account, it typically generates engagement from some individuals at that company. An ad gets clicked. A white paper gets downloaded. A webinar registration comes in. These are positive signals, but on their own they tell an incomplete story.
The critical question is not just whether someone at the account is engaging. It is whether the right people at the account are engaging — and whether enough of them are engaging simultaneously to indicate that a purchase decision is being considered.
In most B2B life science purchases, a single engaged contact is rarely sufficient to move a deal forward. The purchasing process involves multiple stakeholders, each with a distinct perspective and a distinct set of concerns. A scientist who loves your technology cannot unilaterally approve a contract. A procurement manager who sees your pricing as competitive cannot evaluate your technical capabilities. Each member of the buying committee holds a piece of the decision — and failing to engage all of them means the deal can stall or die even when the initial interest is genuine.
This is the gap that committee-level targeting is designed to close.
The Anatomy of a Life Science Buying Committee
Buying committees in B2B life sciences vary by organization size, outsourcing model, and the nature of what is being purchased. But most purchase decisions of meaningful size involve some combination of the following personas:
The Scientific End-User: the researcher, scientist, or clinical specialist who will actually use the solution. This person cares primarily about technical performance, methodological fit, and whether the solution will work for their specific application. Their endorsement is typically a prerequisite for any serious vendor evaluation.
The Program or Project Lead: the Clinical Program Director, Principal Investigator, or Head of Development for the specific program driving the purchasing need. This person cares about timelines, deliverables, and whether the vendor can reliably execute against the program milestones. They often function as the internal champion if the scientific case is strong.
The Procurement or Vendor Management Function: responsible for vendor qualification, contract terms, pricing, and compliance with the organization's purchasing policies. This persona is often invisible in early-stage engagement and becomes critical — and potentially obstructive — later in the process if not engaged proactively.
The Finance or Budget Holder: particularly relevant for larger contracts or early-stage biotechs where capital allocation decisions are made at a senior level. For mid-size and large biotech pharma, the budget approval process may be separated from the technical selection process.
The Legal and Regulatory Function: for purchases with regulatory or IP implications (which is a large proportion of life science vendor relationships), legal and regulatory affairs team members may need to review and approve vendor agreements.
The C-Suite or Senior Leadership: for strategic vendor relationships, preferred provider agreements, or contracts representing a significant portion of the organization's budget, executive-level buy-in is often required. Even when executives are not part of the day-to-day evaluation, their awareness and support is frequently necessary to close a deal.
The practical implication is that a marketing program focused exclusively on the scientific end-user — the most natural audience for technically-oriented content marketing — is engaging only one member of a committee that may include five or more distinct decision-makers. ABM creates the framework to reach all of them.
How ABM Surfaces the Buying Committee
Identifying who is on the buying committee at a specific target account requires both proactive list-building and reactive signal-reading.
Proactive persona mapping starts with your ICP and the buying committee profiles documented for each ICP segment. For a given account, the commercial team uses contact databases and LinkedIn to identify the individuals at that company who hold the titles and roles corresponding to each buying committee persona. These individuals become the named contacts in the contact-level targeting list for that account — the specific people to whom ads will be served, SDR outreach will be directed, and webinar invitations will be sent.
Reactive signal-reading is equally important. Not every buying committee member will be visible in advance. Some are identified only when they begin engaging with campaign content — a new title downloading a gated white paper, a different persona registering for a webinar, an unfamiliar name clicking through from a LinkedIn ad. Each new engagement from a previously unknown contact at a target account is a data point that refines and expands the picture of who the buying committee may include.
Contact-level ABM platforms — Influ2 and Propensity are platforms which enable contact-level targeting and individual-level visibility. Rather than knowing only that someone at a target account engaged, marketers can see precisely which person engaged, with what content, and how many times. When three individuals with different titles — a Biomarker Scientist, a Clinical Program Director, and a Procurement Manager — from the same mid-size biotech all interact with relevant content within a two-week window, this is a strong indication of possible buying-committee level interest. That account should be elevated immediately in scoring and flagged for targeted sales outreach.
Deploying Content That Speaks to Each Persona
Identifying the buying committee is a key step, and one which is enabled by tailored content. Engaging each member of a buying committee effectively requires content and messaging calibrated to each persona's specific concerns — not a single piece of content served to everyone.
This is where the content matrix becomes an essential planning tool. A content matrix maps each buying committee persona to the content types and messages most likely to resonate with them at each stage of the funnel. What it produces in practice is a set of parallel tracks — each targeting a different member of the committee with content relevant to their role — that together build consensus across the full group.
For the scientific end-user, the most effective content is technically substantive: application notes, analytical validation data, peer-reviewed publications, detailed methodology comparisons. This audience wants to see evidence that the solution works and that the team behind it understands the science.
For the program lead, the relevant content shifts toward execution and outcomes: case studies documenting successful program delivery, data on timelines met and milestones achieved, testimonials from peers who have navigated similar program challenges. They need to be confident that the vendor will deliver.
For procurement and finance, the relevant content addresses risk management, vendor qualification, and commercial terms: quality system documentation, regulatory compliance credentials, contract flexibility, pricing transparency, and reference client information.
For senior leadership, the appropriate content is strategic: thought leadership on sector trends, evidence of the vendor's market position and reputation, and any data that positions the relationship as strategically valuable rather than merely transactional.
Running these parallel content tracks through ABM channels — LinkedIn ads targeted by title, contact-level ads to named individuals, email sequences to CRM contacts — means that every member of the buying committee is receiving relevant, role-specific content. This is how consensus is built before the formal vendor evaluation even begins.
A Content Matrix with Examples of Relevant Content by Persona and Engagement Stage
The Pattern of Engagement Is the Signal
The ultimate value of committee-level targeting in ABM is not just that it reaches more people at a target account. It is that the pattern of who is engaging, with what content, and over what timeframe, becomes a reliable indicator of purchase intent.
A single engaged contact might represent genuine interest — or it might represent a researcher doing background reading with no near-term purchasing intent. But when engagement begins to appear across multiple personas at the same account, spanning scientific, operational, and commercial functions, the probability that a buying group is actively evaluating shifts dramatically. The breadth of engagement is the signal.
This is why committee-level visibility changes the nature of the marketing and sales handoff. Instead of passing individual leads to the SDR team and leaving them to figure out whether a deal opportunity exists, a well-instrumented ABM program hands off a picture of the buying committee: which specific individuals have engaged, with which content, and how their engagement maps to the personas typically present when a deal closes. That intelligence turns a cold outreach sequence into a precisely targeted, contextually informed commercial conversation.
The Bottom Line
Targeting accounts is necessary. Targeting buying committees is what makes ABM commercially productive.
The investment required to get there — persona mapping, contact-level targeting infrastructure, parallel content tracks by persona, and the organizational discipline to act on engagement signals quickly — is not trivial. But it is what separates ABM programs that generate genuine pipeline from those that generate engagement data with no clear path to revenue.
In B2B life sciences, where purchasing decisions involve multiple stakeholders and carry real consequences for the programs that depend on them, the ability to surround the full buying committee with relevant, credible, role-specific content before the evaluation formally begins is one of the most durable competitive advantages available.
Why ABM Is Uniquely Powerful in B2B Life Sciences - and Why Generic ABM Tools Often Fall Short
Account-Based Marketing was not invented for the life sciences. It was developed primarily in the B2B technology sector, refined by SaaS companies selling software to enterprise buyers, and packaged into platforms built to serve that context. The intent data that powers most ABM platforms is calibrated to detect when a company is researching a new CRM, evaluating a cybersecurity vendor, or exploring cloud infrastructure options.
Life science companies that approach ABM by simply adopting the SaaS playbook — the same tools, the same intent signals, the same targeting logic — consistently find that the program underperforms. Not because ABM doesn't work in life sciences. Quite the opposite. ABM is arguably more naturally suited to life science commercial environments than to any other B2B sector. But realizing that potential requires understanding what makes life science buyers different, and adapting the approach accordingly.
This post makes the case for why ABM and life sciences are a particularly strong fit — and why the standard tools and playbooks built for tech markets need meaningful adaptation to work in this one.
The Life Science Buyer Is Unlike Any Other B2B Buyer
Before discussing what makes ABM effective in life sciences, it is worth being precise about what makes life science buyers distinctive. Two characteristics stand out above all others.
Scientific skepticism. Life science professionals — whether Principal Scientists, Clinical Program Directors, or VPs of Research — are trained to evaluate evidence. Their entire professional formation is built around the careful assessment of data quality, methodology, and reproducibility. When they encounter marketing, they apply the same analytical lens. Promotional claims without supporting evidence are dismissed. Vendor messaging that is generic, technically shallow, or obviously optimized for persuasion rather than information is tuned out.
This means that the content-driven approach central to ABM — deploying technically substantive, expertise-demonstrating content to engage target personas — is not just a nice-to-have in life sciences. It is the only category of marketing that this audience will meaningfully engage with. White papers grounded in real data, case studies documenting actual clinical or analytical outcomes, webinars led by genuine subject matter experts, technical guides that help scientists solve real problems — these are the currency of life science engagement. ABM provides the framework for deploying that content with precision to the right audience at the right time.
Purchasing conservatism. Life science purchase decisions are not made quickly, and they are not made lightly. The consequences of a poor vendor selection can be significant: a failed assay that delays a clinical trial, a manufacturing partner whose process fails to scale, a CRO whose regulatory expertise proves insufficient at the NDA stage. Vendors are evaluated not just on capability but on track record, regulatory rigor, quality systems, and the depth of the relationship they are willing to build.
This purchasing dynamic plays directly to ABM's structural strengths. ABM is designed for long sales cycles with multiple decision-makers. Its emphasis on nurturing every member of the buying committee over an extended period — building familiarity and credibility across the full group before a formal evaluation begins — aligns precisely with how life science buyers actually make decisions. The companies that are already known, trusted, and perceived as experts when a buying process formally begins have an enormous advantage. ABM is the systematic approach to building that position.
Life Science Accounts Often Contain Multiple Independent Buying Groups
Beyond buyer psychology, life science organizations have a structural characteristic that makes ABM particularly valuable: within a single account, there are often multiple distinct buying groups, each tied to a different program, trial, or research initiative, each with its own decision-makers, timeline, and purchasing needs.
A mid-size biopharmaceutical company running four clinical programs might have a buying group forming around a Phase 2 biomarker program, a separate group evaluating outsourced manufacturing for a Phase 3 asset, and a third group assessing clinical data management solutions for a new trial filing. These three groups share an employer but not a budget, not a decision-making process, and not a set of needs.
In a traditional lead-generation model, engagement from any employee at this company would be pooled into a single account record — and the commercial team would often have no clear picture of which program was generating interest, who the relevant stakeholders were, or which opportunity was most sales-ready. ABM — particularly contact-level ABM using platforms like Influ2 or Propensity — enables a different approach: identifying which individuals at the account are engaging, what content they are engaging with, and therefore which buying group is forming around a specific need. That granularity transforms an ambiguous account into a specific, actionable opportunity.
This reality also means that a single target account in life sciences can yield multiple distinct commercial opportunities over time. An ABM program that successfully engages the first buying group, delivers a strong outcome, and builds a genuine relationship within that account is positioned to identify and engage the next buying group as a new program advances. In life sciences, account depth — the degree to which a vendor is embedded across multiple programs and buying groups within a strategic account — is one of the most important drivers of long-term revenue. ABM is the framework for building it.
Why Standard ABM Tools Miss the Mark in Life Sciences
If ABM is so well-suited to life sciences, why do so many life science companies find that off-the-shelf ABM platforms underdeliver?
The answer lies primarily in intent data. Widely-used tools for determining “intent” and finding in-market accounts like 6Sense and Bombora build their intent models around web search behavior and content consumption patterns detected through publisher networks. These signals are effective at identifying when a company is actively researching a specific category of B2B software: an unusual volume of employees visiting competitor websites, searching industry-specific keywords, or reading relevant analyst reports.
In life sciences, this kind of keyword-based, web-behavior intent data captures only a fraction of the signals that actually predict purchasing intent. The most valuable in-market signals in this sector are explicit, publicly available events that standard ABM platforms are not designed to monitor:
A new funding round — a Series B, C, or D, an IPO, or a significant partnership or licensing deal — almost always triggers program advancement and the engagement of new or expanded vendor relationships. A biotech that just closed a $150M Series C to advance its lead oncology asset into Phase 2 is a highly actionable target. Standard ABM platforms will not surface this signal unless the company coincidentally happens to be searching relevant keywords at the same time.
A clinical trial filing — signals that a specific program is advancing and that a buying group is likely forming around the services and capabilities needed to execute it. These filings are public and structured, but they are not indexed by standard ABM intent platforms.
A regulatory milestone — a Fast Track designation, a Breakthrough Therapy designation, an NDA filing — compresses timelines and creates urgent purchasing needs around the capabilities required to reach or respond to that milestone. These events are highly predictable in their commercial implications, but invisible to standard intent platforms.
Similarly, grant awards in the academic and government research sector — NIH R01s, BARDA contracts, DoD funding — are among the clearest intent signals for vendors serving this segment, and are entirely absent from conventional ABM intent data.
Life science-specific data platforms that aggregate clinical trial registries, funding databases, regulatory filings, pipeline intelligence, and grant award data provide a categorically different quality of intent signal for this sector. Overlaying keyword-based web intent data on top of these signals creates a layered picture of in-market accounts that is far more actionable than either source alone. This is a critical adaptation — and one that requires deliberate attention when building or evaluating a life science ABM program.
The Takeaway
ABM works in life sciences not because it is a clever tactic, but because the structure of the approach maps almost perfectly onto the realities of the market: long sales cycles, conservative buyers, technically demanding audiences, complex multi-stakeholder purchasing processes, and accounts that contain multiple distinct commercial opportunities simultaneously.
What requires adaptation is not the strategic logic of ABM, but the specific tools and data sources used to execute it. Generic intent signals, tech-focused platforms, and SaaS-derived playbooks need to be replaced or supplemented with life-science-specific data intelligence, modality and pipeline-aware targeting, and content strategies calibrated for scientifically trained audiences.
Organizations that make that adaptation — and approach ABM as a life-science-native capability rather than a technology market import — consistently find that it outperforms any other commercial approach available to them.
One to One, One to Few, One to Many: Choosing the Right ABM Model for Your Business
Account-Based Marketing is not a single approach. It exists on a spectrum from highly bespoke, resource-intensive engagement with a handful of elite accounts, to scalable programmatic campaigns reaching hundreds of companies simultaneously. Especially in B2B life sciences marketing, understanding where your organization should sit on that spectrum, and for which accounts, is one of the most consequential decisions in building an effective ABM program.
The three primary ABM models — One-to-One, One-to-Few, and One-to-Many — each serve a distinct purpose, require a different level of resource investment, and produce different types of commercial outcomes. Most mature ABM programs deploy all three simultaneously, applying each to the appropriate tier of the account list. Getting that allocation right is what separates programs that generate strong ROI from those that spread resources too thin or concentrate them in the wrong places.
This post explains each model in detail, how to determine the right fit for your accounts, and how to architect a tiered program that applies the right approach to the right accounts.
Comparing ABM Deployment Frameworks
One-to-One ABM: The Strategic Account Model
One-to-One ABM treats each target account as its own individual market. Every element of the commercial engagement including the content, the advertising, the landing pages, and the BD outreach is customized specifically for that account. This is not personalization at the margins (using a company name in an email subject line). It is a fundamentally account-specific approach in which the marketing and sales investment is calibrated to match the revenue potential of winning that account.
This model is appropriate for a small number of accounts at the very top of your target list — organizations where a secured contract would represent a material impact on annual revenue, and where the complexity and duration of the sales process justify sustained, resource-intensive engagement. In practice, most organizations have between five and twenty accounts in this category, and rarely more than 5% of their total ICP account list.
What One-to-One ABM looks like in practice
For a Tier 1 account, the marketing team develops assets and digital destinations that address the target company specifically. Rather than a generic capabilities landing page, the account receives a purpose-built digital destination that references their known pipeline, their therapeutic or scientific focus, and exactly how your solution is positioned to help with the challenges they are navigating right now.
Content developed for One-to-One ABM might include a custom technical brief mapping your capabilities directly to the account's publicly announced development programs, a bespoke ROI analysis built around their organizational profile, or a thought leadership piece that addresses a specific regulatory or operational challenge the account is known to be facing.
BD and sales engagement runs in parallel: the commercial team maps the buying committee at the account, identifies the internal champion and key decision-makers, and executes highly personalized outreach informed by the specific content each individual has engaged with. Executive-level peer engagement — a meeting between your Chief Scientific Officer and their Head of Clinical Development, for example — is often part of the One-to-One playbook for the most strategic accounts.
The deal threshold that typically justifies One-to-One ABM varies by organization and industry, but in B2B life sciences, it’s generally reserved for accounts with expected contract values in the millions of dollars over a multi-year engagement. Below that threshold, the math rarely works.
One-to-Few ABM: The Scale Model
One-to-Few ABM targets ICP segments or clusters of accounts that share meaningful characteristics — the same therapeutic area, the same development stage, the same outsourcing model, or the same organizational profile. Rather than customizing for each individual account, the commercial team creates messaging and content calibrated to the shared needs of the cluster. The result is a level of relevance and personalization that feels genuinely tailored to each account in the group, without the resource intensity of account-by-account customization.
This is the most versatile of the three ABM models, and for many B2B life science companies it is the most valuable entry point when building an ABM program for the first time. The typical cluster size ranges from ten to one hundred accounts, and the minimum deal threshold that makes the investment worthwhile is generally in the range of $50,000 to $100,000 — though this varies significantly depending on the nature of the offering and the length of the sales cycle.
Building effective clusters
The quality of a One-to-Few campaign depends heavily on how the cluster is constructed. The goal is to find a grouping of accounts with a shared challenge or shared context specific enough that you can speak directly to it in your messaging, and credibly claim genuine expertise in addressing it.
In life sciences, effective ways to segment your ICP to create a target cluster include criteria such as: companies developing assets in a specific modality and development stage (e.g., cell therapy programs in Phase 1/2 transition), companies with a specific funding profile and outsourcing history (e.g., Series B/C biotechs with a CRO-heavy operating model), or companies within a therapeutic area facing a common regulatory inflection point.
The more specific the shared characteristic, the more resonant the messaging can be. A campaign targeting "biotechs with oncology assets preparing for first-in-human trials" can deploy content that addresses the exact operational and scientific challenges that cohort is navigating. That level of specificity is impossible to achieve in a One-to-Many program and unnecessary for One-to-One. One-to-Few is exactly where it becomes commercially leverageable.
What One-to-Few ABM looks like in practice
A One-to-Few campaign typically includes a cluster-specific landing page — not customized by individual account, but built for the segment — along with content assets (white papers, webinars, case studies) directly addressing the cluster's shared challenges. LinkedIn ad campaigns target the relevant personas at the accounts in the cluster, with messaging aligned to each persona's specific role and concerns. SDR outreach sequences are informed by the cluster's shared context, persona-level concerns, and the individual engagement signals generated by the campaign.
The measurement framework for One-to-Few ABM focuses on account-level engagement within the cluster: which accounts are engaging with content, which personas within those accounts are showing up, and which accounts are generating enough engagement signals to warrant elevation to deeper One-to-One treatment or immediate BD outreach.
One-to-Many ABM: The Programmatic Model
One-to-Many ABM extends the program to the broadest segment of the target account universe — the accounts that meet your ICP baseline criteria but do not yet demonstrate the revenue potential or buying signals to warrant the investment of One-to-Few or One-to-One treatment. This group typically represents the majority of the total account list, often 65 to 80% of the ICP.
The purpose of One-to-Many ABM is twofold: build brand familiarity and category authority across a wide pool of potential future customers, and monitor that pool continuously for the engagement signals that indicate an account may be moving into an active buying cycle.
What One-to-Many ABM looks like in practice
At this tier, the commercial approach relies on programmatic advertising and content syndication at scale. Display ads serve consistent, high-level messaging to employees at all accounts on the list — not personalized by account or segment, but relevant to the broader audience defined by the ICP. Educational webinars, industry reports, and published thought leadership serve as broad awareness-building assets that establish credibility and create touchpoints across the account universe.
The intent data generated by One-to-Many campaigns is the primary commercial output. When an account in the One-to-Many pool begins showing elevated engagement — multiple employees visiting the website, specific content being downloaded, ad interaction rates rising — that account becomes a candidate for elevation to One-to-Few or, in some cases, directly to sales and BD outreach.
In this way, One-to-Many ABM functions as an intelligence-gathering layer as much as a marketing one. It keeps your brand visible across the full ICP, while surfacing the accounts that are beginning to move into an active buying cycle before your competitors have identified them.
The Blended Architecture: Running All Three Simultaneously
The most effective ABM programs do not choose one of these models. They run all three concurrently, applying each to the appropriate tier of the account list and allowing accounts to move between tiers as engagement signals and market conditions evolve.
In a well-architected blended program, Tier 1 accounts receive full One-to-One treatment. Tier 2 accounts are organized into One-to-Few clusters based on shared characteristics. The full ICP account universe receives One-to-Many programmatic engagement. The entire system is monitored for the signals — engagement data, intent data, life-science-specific triggers like funding events and clinical trial filings — that indicate an account should be elevated.
This dynamic movement between tiers is one of the defining features of a mature ABM program. The Tier 3 biotech that just closed a Series C and filed a new IND is not a Tier 3 account anymore. A Tier 2 cluster that is generating unusually strong engagement from a specific account may be telling you that account deserves One-to-One treatment. Keeping the system responsive to these signals is what keeps the program efficient over time.
Determining the right blend for your organization
The right distribution across the three models depends on several factors: the nature of your commercial offering, the size of your addressable market, your average deal value, and the maturity of your commercial infrastructure.
Organizations offering highly specialized services with large deal values and a narrow addressable market — a specialized CRO serving only late-phase oncology programs, for example — should weight their investment heavily toward One-to-One and One-to-Few. The market is too small for broad One-to-Many campaigns to generate meaningful ROI, and the revenue potential of each account in the ICP justifies deep investment.
Organizations offering services with broader applicability and moderate deal values such as standardized laboratory testing, research tools, or software platforms will find One-to-Many and One-to-Few doing more of the heavy lifting, with One-to-One reserved for only the largest and most strategically important accounts.
There is no universal ratio. What matters is that the investment at each tier is proportionate to the expected return — and that the intelligence generated at lower tiers is actively used to elevate the right accounts to higher ones.
The Organizing Logic of Tiered ABM
The underlying principle connecting all three models is straightforward: in any commercial program, resources are finite, and deploying them proportionally to expected return is the discipline that drives ROI.
One-to-One, One-to-Few, and One-to-Many are not just tactical variations. They are an expression of that principle and a framework for ensuring that the accounts with the greatest potential receive the investment their potential warrants, while the broader account universe remains engaged and monitored. Getting that balance right is the architecture of an ABM program that grows more effective, and more efficient, over time.
Ready to Build a Smarter Marketing Engine?
Our work helps teams turn complex data into growth — driving qualified leads, higher engagement, and stronger campaign performance across every channel.